Selective internal radiation therapy (SIRT) with Yttrium-90 (Y90) has been historically reserved for unresectable liver malignancy. Evidence is emerging for the use of SIRT to increase future liver remnant (FLR), allowing for resection of previously inoperable disease. Five-year retrospective review of all patients undergoing SIRT with Y90 at a tertiary institute. Patient demographics, clinicopathological data, surgical details and post-operative outcomes were reviewed. The primary outcome, safety of liver resection post-SIRT, was evaluated with 90-day morbidity and mortality. A total of 134 SIRT procedures were performed on 113 patients. Post-SIRT complications occurred in 18 (15.9%) patients, with a single 30-day mortality. Seventeen patients underwent SIRT with the intent to augment FLR for liver resection. Following SIRT, mean hepatic mebrofenin extraction and FLR rose from 2.5%/min/m2 and 30.5% to 4.2%/min/m2 (p=0.01) and 52.5% (p<0.0001), respectively. Ten patients underwent resection and there were two intra-operative complications. The median time from SIRT to resection was 5.2 months. Ninety-day post-operative morbidity was 20% (n=2) and complications were analysed according to the Clavien-Dindo II classification scale. There was no 30-day or 90-day post-operative mortality. Post-SIRT liver resection is a challenging procedure with low post-operative mortality and morbidity.